MEREO BIOPH. ADR LS-,003
Depository Receipt · US5894921072 · MREO · A2PEYJ (LSSI)
2,32 EUR
09.06.2025 18:10
Current Prices from MEREO BIOPH. ADR LS-,003
Exchange | Ticker | Currency | Last Trade | Price | Daily Change |
---|---|---|---|---|---|
![]() NASDAQ |
MREO
|
USD
|
09.06.2025 18:10
|
2,66 USD
| 2,74 USD
-3,14 %
|
Performance
Day | Week | Month | 3 Months | 6 Months | 1 Year | 5 Years |
---|---|---|---|---|---|---|
-4,84 % | 2,81 % | 8,07 % | 1,44 % | -34,92 % | -26,57 % | -2,00 % |
Company Profile for MEREO BIOPH. ADR LS-,003 Depository Receipt
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency. The company has a collaboration with The University of Texas MD Anderson Cancer Center to evaluate anti-TIGIT therapeutic antibody candidate, etigilimab. Mereo BioPharma Group plc was incorporated in 2015 and is based in London, the United Kingdom.
Company Data
Name MEREO BIOPH. ADR LS-,003
Company Mereo BioPharma Group plc
Symbol MREO
Website
https://www.mereobiopharma.com
Primary Exchange
Lang & Schwarz

WKN A2PEYJ
ISIN US5894921072
Asset Class Depository Receipt
Sector Healthcare
Industry Biotechnology
CEO Dr. Denise Vera Scots-Knight Ph.D.
Market Capitalization 351 Mio
Country United Kingdom
Currency EUR
Employees 0,0 T
Address One Cavendish Place, W1G 0QF London
IPO Date 2019-04-24
Ticker Symbols
Name | Symbol |
---|---|
Frankfurt | MAH0.F |
NASDAQ | MREO |
More Shares
Investors who MEREO BIOPH. ADR LS-,003 hold also have the following shares in their portfolio:
The financial platform MoneyPeak tracks and analyzes investments and portfolios.
From securities portfolios to crypto purchases.
Useful, simple, and free. Stocks, ETFs, ETCs, ETNs, indices, funds, bonds, certificates, currencies, options, rights issue.
Useful, simple, and free. Stocks, ETFs, ETCs, ETNs, indices, funds, bonds, certificates, currencies, options, rights issue.